AAM Urges US Senate To Back Domestic Production
AAM Insists The Supply Chain Is Safe, But Could Be Improved
While the AAM is lobbying for a renewed focus on domestic drug production amid fresh concerns about the globalization of the US pharmaceutical drug supply chain, the association has urged US Congress to have confidence in FDA oversight, insisting that “the US has one of the safest drug supply chains in the world.”